Hebecavir Dosage/Direction for Use

Compensated liver disease: Nucleoside-naïve patients: the recommended dose in adults is 0.5 mg once daily, with or without food.
Lamivudine-refractory patients (i.e. history of hepatitis B viremia while receiving lamivudine therapy or known lamivudine resistance [LVDr, commonly called YMDD] mutations): the recommended dose is 1 mg once daily, which must be taken orally on an empty stomach (empty means at least 2 hours before and at least 2 hours after a meal).
Decompensated liver disease: The recommended dose for patients with decompensated liver disease is 1 mg once daily, which must be taken on an empty stomach (empty means at least 2 hours before and at least 2 hours after a meal).
Special Populations: Patients with Renal Impairment: Entecavir is predominantly eliminated by the kidney. The clearance of entecavir decreases with impaired (decreasing) creatinine clearance.
Dosage adjustment of HEBECAVIR is recommended for patients who have a creatinine clearance <50 mL/min, including those on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD), as shown in Table 1. (See Table 1.)

Click on icon to see table/diagram/image

Patients with hepatic impairment: No dosage adjustment of HEBECAVIR is required for patients with hepatic impairment.
Pediatric and adolescent patients: The safety and efficacy of HEBECAVIR in patients <16 years of age have not been established.
Geriatric patients: No dosage adjustment of HEBECAVIR based on age is required.
Route of Administration: Oral administration. HEBECAVIR should be taken orally.